LSK Global PS, in charge of clinical trials related to Hoystar’s COVID-19
Sisa Week = Reporter Jegalmin Daewoong Pharmaceutical is working on joint clinical development of COVID-19 treatment with LSK Global Pharma Service.
Daewoong Pharmaceutical announced on the 21st that it has signed a memorandum of understanding (MOU) with LSK Global PS and Hoystar Tablet (ingredient name: Camostat mesylate) for joint development of clinical trials for COVID-19 treatment. LSK Global PS is known as a leading clinical trial agency (CRO) in Korea.
The purpose of this MOU is to contribute to the acceleration of development by establishing a joint clinical development system through cooperation in the clinical development of Hoystar tablets for COVID-19 treatment, sharing human resources and infrastructure for clinical trials, and establishing clinical strategies.
Through the signing of the MOU, LSK Global PS performs tasks throughout the clinical trial, including monitoring, clinical trial operation, data management, and statistics. In addition, it is responsible for some or the entire process in several clinical trials of Hoystar tablets on the prevention and treatment of Corona 19. It is planning to cooperate on strategies and development directions for expanding global clinical trials not only in Korea but also overseas.
Hoy Star Tablet is a drug being developed by Daewoong Pharmaceutical as the first oral Corona 19 treatment in Korea, and according to the company, it has confirmed the improvement of clinical symptoms and rapid virus removal rate in patients with mild Corona 19 disease in Korea. Accordingly, a phase 2/3 clinical trial has been initiated for large-scale patients. Phase 2/3 is approved by combining the phase 3 trial with the existing phase 2 clinical trial, and has the advantage of enabling rapid research on large-scale patients.
In addition, clinical trials for preventive purposes were recently approved by the Ministry of Food and Drug Safety, so that close contact, suspected symptomatic and self-isolators can develop a drug that should be taken the fastest, and from next month, Samsung Seoul Hospital and Asan Hospital. It is planning to conduct clinical trials in 1,012 people in alphabetical order. In addition, a large-scale national study (Korean Covid-19 Trial 1) clinical trial on severe corona19 patients, which has not been conducted in Korea, is also being conducted.
Seung-ho Jeon, President of Daewoong Pharmaceutical, said, “Hoy Star Tablet is a drug that can be used in a wide range of patients, and we expect that it will greatly contribute to overcoming the global COVID-19 pandemic.” , I will try to provide COVID-19 treatment to patients as soon as possible.”
Lee Young-jak, CEO of LSK Global PS, said, “It is meaningful that LSK Global PS can contribute to the end of Corona 19 by in charge of clinical trials related to Corona 19 of Daewoong Pharmaceutical including Hoy Star. “We will do our best to quickly and successfully complete the clinical trial of Hoystar Pharmaceutical Covid-19,” he said.
Copyright © Sisaweek Unauthorized reproduction and redistribution prohibited